These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 1971978

  • 21. Receptor binding characteristics and pharmacokinetic properties as a tool for the prediction of clinical effects of beta-blockers.
    Wellstein A, Palm D, Belz GG, Pitschner HF.
    Arzneimittelforschung; 1985; 35(1):2-6. PubMed ID: 2859024
    [Abstract] [Full Text] [Related]

  • 22. What is preferable in unstable angina, beta-blockade or calcium-inhibition?
    Hugenholtz PG, Serruys PW, Simoons ML.
    Arch Mal Coeur Vaiss; 1983 Feb; 76 Spec No():199-209. PubMed ID: 6134510
    [Abstract] [Full Text] [Related]

  • 23. Propranolol stereoselectively inhibits alpha-adrenoceptor-mediated vasoconstriction in mesenteric arterial beds of rats.
    Stauber RE, Heinemann A.
    J Auton Pharmacol; 1996 Jun; 16(3):125-9. PubMed ID: 8884459
    [Abstract] [Full Text] [Related]

  • 24. Structural basis for enantiomer binding and separation of a common beta-blocker: crystal structure of cellobiohydrolase Cel7A with bound (S)-propranolol at 1.9 A resolution.
    Ståhlberg J, Henriksson H, Divne C, Isaksson R, Pettersson G, Johansson G, Jones TA.
    J Mol Biol; 2001 Jan 05; 305(1):79-93. PubMed ID: 11114249
    [Abstract] [Full Text] [Related]

  • 25. Different stereoselective effects of (R)- and (S)-propafenone: clinical pharmacologic, electrophysiologic, and radioligand binding studies.
    Stoschitzky K, Klein W, Stark G, Stark U, Zernig G, Graziadei I, Lindner W.
    Clin Pharmacol Ther; 1990 Jun 05; 47(6):740-6. PubMed ID: 2162749
    [Abstract] [Full Text] [Related]

  • 26. Stereoselective vascular effects of the (R)- and (S)-enantiomers of propranolol and atenolol.
    Stoschitzky K, Lindner W, Kiowski W.
    J Cardiovasc Pharmacol; 1995 Feb 05; 25(2):268-72. PubMed ID: 7752652
    [Abstract] [Full Text] [Related]

  • 27. [15 years of therapy with beta-receptor blockers. Tendency for differentiation].
    Kersting F, Kasper W, Meinertz T.
    Med Klin; 1979 Aug 10; 74(32-33):1179-88. PubMed ID: 38385
    [No Abstract] [Full Text] [Related]

  • 28. [Withdrawal phenomena after chronic beta-blockade. Causes and therapeutic consequences].
    Krämer B, Kübler W.
    Dtsch Med Wochenschr; 1984 Mar 23; 109(12):465-71. PubMed ID: 6142815
    [No Abstract] [Full Text] [Related]

  • 29. [Beta blockers today].
    Nieminen MS, Partanen J.
    Nord Med; 1992 Mar 23; 107(5):150-2, 156. PubMed ID: 1351282
    [Abstract] [Full Text] [Related]

  • 30. Nadolol: a new beta-adrenoceptor antagonist.
    Frishman WH.
    N Engl J Med; 1981 Sep 17; 305(12):678-82. PubMed ID: 6115316
    [No Abstract] [Full Text] [Related]

  • 31. Beta-adrenoceptor blockade and intrinsic sympathomimetic activity--relevance in the treatment of ischaemic heart disease.
    Northcote RJ, Ballantyne D.
    Scott Med J; 1985 Oct 17; 30(4):208-15. PubMed ID: 2869581
    [Abstract] [Full Text] [Related]

  • 32. An enantiomer-enantiomer interaction of (S)- and (R)-propafenone modifies the effect of racemic drug therapy.
    Kroemer HK, Fromm MF, Bühl K, Terefe H, Blaschke G, Eichelbaum M.
    Circulation; 1994 May 17; 89(5):2396-400. PubMed ID: 7910120
    [Abstract] [Full Text] [Related]

  • 33. Enantiomers: implications and complications in developmental pharmacology.
    Eichelbaum M.
    Dev Pharmacol Ther; 1992 May 17; 18(3-4):131-4. PubMed ID: 1306801
    [Abstract] [Full Text] [Related]

  • 34. Exercise increases plasma concentrations of (R)- and (S)-propranolol.
    Stoschitzky K, Schumacher M, Stark G, Dimai HP, Stauber R, Stoschitzky P, Krejs GJ, Klein W, Lindner W.
    Eur J Clin Pharmacol; 1996 May 17; 50(4):339-42. PubMed ID: 8803530
    [Abstract] [Full Text] [Related]

  • 35. Stereoselective hemodynamic effects of (R)-and (S)-propranolol in man.
    Stoschitzky K, Lindner W, Rath M, Leitner C, Uray G, Zernig G, Moshammer T, Klein W.
    Naunyn Schmiedebergs Arch Pharmacol; 1989 Apr 17; 339(4):474-8. PubMed ID: 2739756
    [Abstract] [Full Text] [Related]

  • 36. Protection from morbidity and mortality from first infarcts: the case for beta-blockade.
    Lambert DM.
    Aust Fam Physician; 1978 Jun 17; Suppl():5-10. PubMed ID: 708313
    [Abstract] [Full Text] [Related]

  • 37. beta-Adrenoreceptor antagonistic actions and mutagenicities of R(+)- and S(-)-enantiomers of N-desisopropylpropranolol and its N-acetyl conjugate.
    Ono Y, Wu X, Noda A, Noda H, Takeo S, Nasa Y, Isayama Y, Imai M, Sera N.
    Biol Pharm Bull; 1997 Jan 17; 20(1):61-5. PubMed ID: 9013808
    [Abstract] [Full Text] [Related]

  • 38. Microbial production of phase I and phase II metabolites of propranolol.
    Marvalin C, Azerad R.
    Xenobiotica; 2011 Mar 17; 41(3):175-86. PubMed ID: 21110747
    [Abstract] [Full Text] [Related]

  • 39. [beta Blocking agents in arterial hypertension].
    Zacchello F.
    Minerva Pediatr; 1977 Mar 03; 29(7):435-8. PubMed ID: 17060
    [No Abstract] [Full Text] [Related]

  • 40. beta-adrenergic blocking drugs in psychiatry: present status, future approaches and research.
    Atsmon A, Blum I.
    Encephale; 1978 Mar 03; 4(2):173-86. PubMed ID: 28941
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.